UBS Group’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $57.4M | Sell |
5,093,068
-1,704,135
| -25% | -$19.2M | 0.01% | 1105 |
|
|
2025
Q1 | $68.6M | Buy |
6,797,203
+1,507,429
| +28% | +$15.2M | 0.01% | 952 |
|
|
2024
Q4 | $62.6M | Buy |
5,289,774
+4,779,042
| +936% | +$56.5M | 0.01% | 974 |
|
|
2024
Q3 | $5.89M | Buy |
510,732
+16,383
| +3% | +$189K | ﹤0.01% | 2132 |
|
|
2024
Q2 | $5.23M | Sell |
494,349
-43,248
| -8% | -$457K | ﹤0.01% | 2109 |
|
|
2024
Q1 | $5.67M | Buy |
537,597
+303,708
| +130% | +$3.2M | ﹤0.01% | 2077 |
|
|
2023
Q4 | $2.63M | Buy |
233,889
+3,543
| +2% | +$39.8K | ﹤0.01% | 2595 |
|
|
2023
Q3 | $2.69M | Sell |
230,346
-148,704
| -39% | -$1.74M | ﹤0.01% | 2319 |
|
|
2023
Q2 | $3.82M | Buy |
379,050
+371,480
| +4,907% | +$3.74M | ﹤0.01% | 2123 |
|
|
2023
Q1 | $55.9K | Sell |
7,570
-153,442
| -95% | -$1.13M | ﹤0.01% | 5291 |
|
|
2022
Q4 | $1.29M | Buy |
+161,012
| New | +$1.29M | ﹤0.01% | 2935 |
|